Great points Respert24. In my opinion, all successful drugs are at risk of Chinese knockoff, no matter where the drug is invented, manufactured or distributed. While I was initially hesitant about a Chinese partnership, it could actually prove beneficial in that regard, sort of a "if you can't beat em, join em" scenario. If the drug is licensed legally and a Chinese company profits from it (along with their government) hopefully, there will be less pressure for China to steal it. In fact, Qilu may defend its legal rights to it, against other Chinese companies trying to knock it off.

One thing I am pleased about, if this scenario turns out to be true, is Qilu has a lot of experience with regulatory approvals worldwide. While I love the idea of a Samsung partnership, I don't know how deep their bench is?

Several of you kind posters have pointed out to me that I misspoke in my post yesterday about Carboplatin. My apologies, it was actually in use in the Tnbc trials, not at MD Anderson, which is a combo trial with checkpoint inhibitors. Carboplatin is one of the drugs in Qilu's portfolio, so I'm sure they were very keen on the results of our Tnbc trials with Carboplatin.

Now, we hear that our Chairman of the Board, Tanya Durkee Urbach, majored in Chinese. Thanks for the info Artistsview. She literally has a B.A. in Chinese.

Let's hope there is some big news next week. I've been trying not to blink but geez my eyes are tired.